Search

Displaying results 1301 - 1310 of 7687 in total
  1. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    received an ALK-inhibitor on December 18, 2024. … [A265030] Ensartinib was approved by the FDA for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously

  2. Drug

    Triheptanoin

    go.drugbank.com/drugs/DB11677
    ApprovedInvestigational

    [A214817] Triheptanoin was granted FDA approval on 30 June 2020.[L14612] … Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation.

  3. Drug

    Omega-3 fatty acids

    go.drugbank.com/drugs/DB11133
    ApprovedInvestigationalNutraceutical

    Omega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with a double bond at the third carbon atom from the end of the carbon chain. The three types of omega-3 fatty acids involved in human physiology are α-linolenic acid (ALA) (fou...

    Mixtures: Animi-3 with Vitamin D, Se-Tan DHA
  4. Drug

    Carboxymethylcellulose

    go.drugbank.com/drugs/DB11059
    ApprovedInvestigational

    Carboxymethylcellulose is a cellulose derivative that consists of the cellulose backbone made up of glucopyranose monomers and their hydroxyl groups bound to carboxymethyl groups. It is added in food products as a viscosity modifier or t...

    Mixtures: OPTIVE FUSION UD, OPTIVE FUSION® UD
  5. Drug

    Recombinant stabilized RSV A prefusion F antigen

    go.drugbank.com/drugs/DB18713
    ApprovedInvestigational

    [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of

  6. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. … [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  7. Drug

    Clidinium

    go.drugbank.com/drugs/DB00771
    Approved

    It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.

    Synonyms: Bromuro de clidinio, Bromure de ClidiniumMixtures: Nu-chlorax Capsules USP
  8. Drug

    Fosfomycin

    go.drugbank.com/drugs/DB00828
    ApprovedInvestigational

    [A230348] In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring. … [A230378] Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria.

    Products: FOSFOCIL GU
  9. Drug

    Voretigene neparvovec

    go.drugbank.com/drugs/DB13932
    ApprovedInvestigational

    [A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095] … Voretigene Neparvovec-rzyl (VN-rzyl) is an adeno-associated virus vector-based gene therapy.[L1094] An adeno-associated virus is a small virus that infects humans and other primates.

  10. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]